Triggering Innate Immune Receptors as New Therapies in Alzheimer’s Disease and Multiple Sclerosis
Multiple sclerosis and Alzheimer’s disease are two complex neurodegenerative diseases involving the immune system. So far, available treatments provide at best mild improvements to patients’ conditions. For decades now, a new set of molecules have been used to modulate and regulate the innate immuni...
Main Authors: | Pierre-Alexandre Piec, Vincent Pons, Serge Rivest |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/8/2164 |
Similar Items
-
Muramyl Dipeptide Administration Delays Alzheimer’s Disease Physiopathology via NOD2 Receptors
by: Pierre-Alexandre Piec, et al.
Published: (2022-07-01) -
Triggering of NOD2 Receptor Converts Inflammatory Ly6Chigh into Ly6Clow Monocytes with Patrolling Properties
by: Anne-Julie Lessard, et al.
Published: (2017-08-01) -
The role of NOD-like receptors in innate immunity
by: Cássio Luiz Coutinho Almeida-da-Silva, et al.
Published: (2023-03-01) -
Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer’s Disease and Multiple Sclerosis
by: Adham Fani Maleki, et al.
Published: (2019-07-01) -
Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases
by: Katarzyna Wicherska-Pawłowska, et al.
Published: (2021-12-01)